ClinicalTrials.govpublic full text
Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients
metastatic breast cancer, human epidermal growth factor 2 negative carcinoma of breast, breast cancer, her2negative, second line treatment, her2-, mbc, metastatic, bevacizumab, eribulin, human epidermal growth factor receptor 2-negative, interventional
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 800803
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.